• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Evaluation of Reconstructive Techniques for Anterior and Middle Skull Base Defects Following Tumor Ablation
Conclusions: Vascularized flaps provide reliable and durable reconstructive options for anterior and middle skull base defects after resection of large complex malignant neoplasms of the craniofacial region. Free flaps, such as RFFFs, ALTs, and TDAPs, are well suited for these defects. They have a low risk of complications and low donor-site morbidity and offer good functional and esthetic outcomes.
Source: Journal of Oral and Maxillofacial Surgery - July 15, 2013 Category: ENT & OMF Authors: Jayini S. Thakker, Rui Fernandes Tags: Surgical Oncology and Reconstruction Source Type: research